Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLACIER: Gedatolisib and Hydroxychloroquine for Prevention of Recurrent Breast Cancer
NCT03400254Phase 2Withdrawn
- Sponsor
- Abramson Cancer Center
- Start
- Feb 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gedatolisib in breast cancer, sponsored by Abramson Cancer Center. Planned start Feb 2019; status: withdrawn.
02
Drugs
gedatolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03400254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03400254.